The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer.
M. J. Birrer
No relevant relationships to disclose
P. Konstantinopoulos
No relevant relationships to disclose
R. T. Penson
Research Funding - Massachusetts General Hospital
M. Roche
No relevant relationships to disclose
A. Ambrosio
No relevant relationships to disclose
T. E. Stallings
Employment or Leadership Position - BiPar Sciences
U. Matulonis
No relevant relationships to disclose
C. R. Bradley
Employment or Leadership Position - BiPar Sciences